DV
Dividend Vision

CTXR — Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc (CTXR)

Total return is -99.8% over the past 11.9 years, 486.0 points behind SPY at 386.2%. Its deepest 1-year drawdown was 73.6%.

Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing critical care products, including LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage pipeline candidates for catheter-related infections, hemorrhoid treatment, and acute respiratory distress syndrome. The company does not currently distribute dividends. Citius Pharmaceuticals appeals primarily to investors seeking exposure to clinical-stage and early commercial biopharmaceutical development rather than current income.

CTXR key facts

Asset type
Stock
Asset class
Equity
Inception date
10/02/2014
Last close
$0.76
Market cap
$13,610,984
Average volume
591200.0
Payment date
06/09/2017
Beta
0.981
Payout ratio
0.0
Forward P/E
0.3181
EPS
$-2.14